VR Logo

Akero Therapeutics Inc. (AKRO) download report


Healthcare | Biotechnology & Pharma Research

Akero Therapeutics Inc. (AKRO) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health.

IPO Date: 20-Jun-2019

Pres, CEO & Director: Dr. Andrew Cheng M.D., Ph.D.

Co-Founder, Exec. VP, COO & Sec.: Dr. Jonathan M. Young J.D., Ph.D.

Listing: NASDAQ: AKRO

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.akerotx.com

Key Facts

Market cap: $359.34 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-111.72 Mln

Cash: $165.38 Mln

Total Debt: $1.47 Mln

Insider's Holding: 8.12%

Liquidity: Low

52 Week range: $7.52 - 26.98

Shares outstanding: 37,548,200

5 Years Aggregate:

  • CFO: $-195.52 Mln
  • EBITDA: $-240.41 Mln
  • Net Profit: $-310.02 Mln

Stock Performance

Time Period Akero Therapeutics (AKRO) S&P BSE Sensex S&P Small-Cap 600
YTD-52.96-9.18-18.76
1 month12.54-4.78-7.98
3 months-29.89-9.66-13.63
1 Year-59.900.81-17.17
3 Years-19.6110.336.11
5 Years--11.345.88
10 Years--11.749.84
As on 01-Jul-2022
Year Akero Therapeutics (AKRO) S&P Small-Cap 600 S&P BSE Sensex
2021-18.0225.2721.99
202016.249.5715.75